Fundraising Fox
Helus Pharma
NASDAQ: HELPToronto, CA · Founded 2019 · 6 known investors
Find your way into Helus Pharma
Sign up to see every warm intro you have to Helus Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Helus Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Helus Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions such as depression, anxiety, schizophrenia, and bipolar disorder. It focuses on advancing novel treatments for mental health disorders through clinical development and commercialization.
Founders & leadership
Helus Pharma was founded in 2019 by Eric So, John Kanakis, and Paul Glavine.
ES
Eric SoCo-Founder, Executive ChairmanEric So is co-founder and executive chairman of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions. He has held C-level roles in corporate strategy, development, and finance across public and private companies at various stages of growth.
JK
John KanakisCo-FounderJohn Kanakis is co-founder of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and neurological conditions. He brings approximately 25 years of experience across private and public companies, with a track record of founding multiple ventures in biotech, medtech, cleantech, AI, and cybersecurity sectors.
PG
Paul GlavineCo-Founder and Chief Growth OfficerPaul Glavine is Co-Founder and Chief Growth Officer at Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions. He also serves as Chairman of the Board at LongPoint ETFs, a firm focused on Canadian ETF strategies.
GF
Gabriel FahelExecutive
DD
Douglas DrysdaleExecutive
JP
Jacqueline PoriadjianExecutive
MH
Michael HalsteadChief Executive OfficerMichael Halstead is Chief Executive Officer of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies targeting psychiatric and CNS conditions including depression and anxiety.
MC
Michael ColaChief Executive Officer
AB
Aaron BartloneChief Operating OfficerAaron Bartlone is Chief Operating Officer of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS disorders. He has extensive experience in product development, clinical trials, regulatory affairs, and commercialization across the biopharmaceutical industry, with involvement in nine new drug commercializations.
LC
Lori ChallengerChief Compliance, Ethics & Administrative OfficerLori Challenger is Chief Compliance, Ethics & Administrative Officer at Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions. She brings over 20 years of experience in compliance, governance, organizational transformation, and people operations across startups, scale-ups, and publicly traded companies in regulated industries.
AI
Amir InamdarChief Medical OfficerAmir Inamdar is a psychiatrist with over 20 years of experience in clinical research and drug development for psychiatric disorders. He has led clinical trial design and regulatory strategy for novel psychiatric therapeutics, including first-in-human, proof-of-concept, and pivotal studies.
AN
Alex NivorozhkinChief Scientific OfficerAlex Nivorozhkin is Chief Scientific Officer of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS disorders. He has held senior executive roles and contributed inventions in life sciences and pharmaceuticals.
Investors · 6
Funding
SEC filings, press & company announcements$218M disclosed across 10 of 34 rounds · 2020–2026
- Undisclosed amountstock offeringJul 2026Source ↗
▶$262KofferedSep 2026 · 4 investors · OtherRule 506(b)
▶$262KofferedSep 2026 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric SoExecutive Officer, Director
- Michael HalsteadExecutive Officer
- Greg CaversExecutive Officer
- Paul GlavineExecutive Officer, Director
- Gabriel FahelExecutive Officer
- Alex NivorozhkinExecutive Officer
- Aaron BartloneExecutive Officer
- George TzirasExecutive Officer
- Amir InamdarExecutive Officer
- Theresa FirestoneDirector
- Mark LawsonDirector
- Grant FroeseDirector
- Eric HoskinsDirector
- Freda Lewis-HallDirector
- Offering amount
- $262K
- First sale
- Aug 2026
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶Undisclosed amountofferedAug 2026 · 1 investors · OtherRule 506(b)
▶Undisclosed amountofferedAug 2026 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric SoExecutive Officer, Director
- Michael HalsteadExecutive Officer
- Greg CaversExecutive Officer
- Paul GlavineExecutive Officer, Director
- Gabriel FahelExecutive Officer
- Alex NivorozhkinExecutive Officer
- Aaron BartloneExecutive Officer
- George TzirasExecutive Officer
- Amir InamdarExecutive Officer
- Theresa FirestoneDirector
- Mark LawsonDirector
- Grant FroeseDirector
- Eric HoskinsDirector
- Freda Lewis-HallDirector
- First sale
- Aug 2026
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶Undisclosed amountofferedAug 2026 · 2 investors · OtherRule 506(b)
▶Undisclosed amountofferedAug 2026 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric SoExecutive Officer, Director
- Michael HalsteadExecutive Officer
- Greg CaversExecutive Officer
- Paul GlavineExecutive Officer, Director
- Gabriel FahelExecutive Officer
- Alex NivorozhkinExecutive Officer
- Aaron BartloneExecutive Officer
- George TzirasExecutive Officer
- Amir InamdarExecutive Officer
- Theresa FirestoneDirector
- Mark LawsonDirector
- Grant FroeseDirector
- Eric HoskinsDirector
- Freda Lewis-HallDirector
- First sale
- Aug 2026
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶$511.7KofferedJul 2026 · 13 investors · OtherRule 506(b)
▶$511.7KofferedJul 2026 · 13 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric SoExecutive Officer, Director
- George TzirasExecutive Officer
- Gabriel FahelExecutive Officer
- Paul GlavineExecutive Officer, Director
- Greg CaversExecutive Officer
- Aaron BartloneExecutive Officer
- Amir InamdarExecutive Officer
- Theresa FirestoneDirector
- Mark LawsonDirector
- Grant FroeseDirector
- Eric HoskinsDirector
- Freda Lewis-HallDirector
- Offering amount
- $511.7K
- First sale
- Jul 2026
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶Undisclosed amountofferedJul 2026 · 5 investors · OtherRule 506(b)
▶Undisclosed amountofferedJul 2026 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric SoExecutive Officer, Director
- George TzirasExecutive Officer
- Gabriel FahelExecutive Officer
- Paul GlavineExecutive Officer, Director
- Greg CaversExecutive Officer
- Aaron BartloneExecutive Officer
- Amir InamdarExecutive Officer
- Theresa FirestoneDirector
- Mark LawsonDirector
- Grant FroeseDirector
- Eric HoskinsDirector
- Freda Lewis-HallDirector
- First sale
- Jul 2026
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶Undisclosed amountofferedMar 2026 · 1 investors · OtherRule 506(b)
▶Undisclosed amountofferedMar 2026 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Theresa FirestoneDirector
- Gabriel FahelExecutive Officer
- Mark LawsonDirector
- Grant FroeseDirector
- George TzirasExecutive Officer
- Paul GlavineDirector, Executive Officer
- Michael ColaExecutive Officer
- Eric HoskinsDirector
- Eric SoDirector, Executive Officer
- Greg CaversExecutive Officer
- Aaron BartloneExecutive Officer
- First sale
- Mar 2026
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶$114.2KofferedJan 2026 · 3 investors · OtherRule 506(b)
▶$114.2KofferedJan 2026 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric HoskinsDirector
- Theresa FirestoneDirector
- Gabriel FahelExecutive Officer
- Aaron BartloneExecutive Officer
- Greg CaversExecutive Officer
- Grant FroeseDirector
- Eric SoDirector, Executive Officer
- Paul GlavineDirector, Executive Officer
- George TzirasExecutive Officer
- Mark LawsonDirector
- Offering amount
- $114.2K
- First sale
- Dec 2025
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶$288.6KofferedNov 2025 · 5 investors · OtherRule 506(b)
▶$288.6KofferedNov 2025 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric SoDirector, Executive Officer
- Aaron BartloneExecutive Officer
- Eric HoskinsDirector
- George TzirasExecutive Officer
- Greg CaversExecutive Officer
- Mark LawsonDirector
- Theresa FirestoneDirector
- Paul GlavineDirector, Executive Officer
- Gabriel FahelExecutive Officer
- Grant FroeseDirector
- Offering amount
- $288.6K
- First sale
- Nov 2025
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Helus Pharma do?
- Helus Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions such as depression, anxiety, schizophrenia, and bipolar disorder. It focuses on advancing novel treatments for mental health disorders through clinical development and commercialization.
- Who founded Helus Pharma?
- Helus Pharma was founded by Eric So, John Kanakis, Paul Glavine in 2019.
- Who are Helus Pharma's investors?
- Helus Pharma's investors include Awareness Venture, Bailey Venture Partners, Innovating Capital, JLS, Noetic, O2h Ventures.
- How much funding has Helus Pharma raised?
- Helus Pharma has disclosed $218M raised across 10 of its 34 known rounds.
- Where is Helus Pharma headquartered?
- Helus Pharma is headquartered in Toronto, CA.